Loading…
Leading global distributor of dental and medical supplies/equipment to office-based practitioners, plus practice-management software.
Leading global distributor of dental and medical supplies/equipment to office-based practitioners, plus practice-management software.
Buys supplies in bulk from manufacturers and resells them to thousands of small dental and medical practices for a modest markup, so service, delivery and credit terms are the competitive points. Equipment and software, including Dentrix practice-management software, tie customers in. It spun off its animal-health arm into Covetrus in 2019.
Moat: narrow (scale, distribution, switching costs). Broad catalog and logistics reach to fragmented dental/medical practices, reinforced by practice-management software lock-in.
Headquarters: Melville, New York, USA · Founded: 1932 · Employees: 25,000
Size Henry Schein (HSIC) is a United States Health Care company (Medical Distributors) with a market value of $9.51B, the 801st largest of 3,117 United States companies the cockpit tracks. Shares closed at $86.05 on 6 Nov 2026.
Performance Over six months the shares gained 21.5%, against +6.3% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 11 in its peer set.
Growth Revenue grew 6.2% over the last twelve months (peer median +5.4%); the operating margin is 6.0% (peer median 3.4%).
Valuation It trades at 14.8× forward earnings against a peer median of 17.4× (4th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.6 points below its cost of capital (8.1% WACC).
Short interest Short interest is 8.1% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $13.7B | $13.2B | $12.7B | $12.3B | $12.6B |
| Revenue growth | — | +4% | +3% | -2% | — |
| Gross profit | $4.06B | $3.84B | $3.77B | $3.65B | $3.65B |
| EBITDA | $1.16B | $1.09B | $1.03B | $962M | $1.15B |
| Net income | $421M | $398M | $390M | $416M | $538M |
| Free cash flow | $559M | $573M | $700M | $353M | $506M |
| Capital expenditure | $187M | $191M | $187M | $187M | $96.0M |
| Total debt | $3.89B | $3.44B | $2.87B | $2.74B | $1.50B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Henry Schein HSIC | $9.51B | +22% | +6% | 6% | 14.8× | 9.8% |
| Envista NVST | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% |
| McKesson MCK | $124B | +44% | +9% | 2% | 21.8× | -4.8% |
| Medline MDLN | $52.1B | 0% | +12% | 6% | 26.1× | 17.1% |
| Cardinal Health CAH | $62.9B | +48% | +14% | 1% | 20.8× | 8.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HSIC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.7% | +4.8% | 3rd lowest of 11 |
| 6-month return | +21.5% | +6.3% | 3rd highest of 11 |
| Distance from 52-week high | -6.7% | -14.5% | 2nd highest of 11 |
| Revenue growth (TTM) | +6.2% | +5.4% | 6th highest of 11 |
| Operating margin | 6.0% | 3.4% | 3rd highest of 11 |
| Forward P/E | 14.8× | 17.4× | 4th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 9.8% | 0.1% | 2nd most demanding of 10 |
| Growth delivered (Del g) | +5.4% | +4.0% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | +4.4 pp | -7.7 pp | 2nd most demanding of 10 |
| ROIC minus cost of capital | -0.6 pp | +0.9 pp | 3rd lowest of 11 |
| EV / EBITDA | 12.8× | 8.4× | 2nd most expensive of 4 |
| Net debt / EBITDA | 3.2× | 0.6× | 2nd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Henry Schein HSIC | United States | $9.51B | +22% | +6% | 6% | 14.8× | 9.8% | +5.4% |
| Sinopharm 1099.HK | Hong Kong | $6.83B | -4% | +3% | 3% | 6.3× | -8.1% | +4.0% |
| DKSH DKSH.SW | Switzerland | $6.10B | +29% | -1% | 3% | 21.5× | -1.4% | +0.6% |
| Galenica GALE.SW | Switzerland | $5.46B | +8% | +6% | 5% | 23.4× | 6.9% | +3.5% |
| Jointown Pharmaceutical 600998.SS | China | $3.96B | +1% | +9% | 2% | 11.7× | 0.1% | +7.8% |
| Amplifon AMP.MI | Italy | $3.72B | +13% | 0% | 9% | 18.1× | 9.5% | +9.8% |
| MEDIPAL 7459.T | Japan | $3.67B | +14% | +4% | 1% | 12.6× | -7.4% | +3.5% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.20B | +5% | +9% | 4% | 15.7× | n/a | n/a |
| Asker Healthcare ASKER.ST | Sweden | $2.98B | -5% | +12% | 7% | 26.6× | 1.2% | +12.7% |
| Alfresa 2784.T | Japan | $2.79B | -3% | +5% | 1% | 17.4× | -9.1% | +3.5% |
| Hanmi Science 008930.KS | South Korea | $2.71B | +44% | +6% | 5% | n/a | 24.2% | +9.6% |